TGFβ promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells

https://pubmed.ncbi.nlm.nih.gov/33207077/

Mol Oncol. 2021 Feb;15(2):679-696. doi: 10.1002/1878-0261.12857. Epub 2020 Dec 5.

Jeong-Yun Choi ¹, Haeseung Lee ², Eun-Ji Kwon ¹, Hyeon-Joon Kong ¹, Ok-Seon Kwon ³, Hyuk-Jin Cha ^1 4Affiliations expand

• PMID: 33207077
• PMCID: PMC7858114
• DOI: 10.1002/1878-0261.12857

Abstract

The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial-to-mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal-type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal-type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP-dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal-type lung cancer.

Keywords: AXL; EMT; TGFβ-SMAD4; YAP; doxorubicin; resistance.